FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W792640976> ?p ?o ?g. }

• W792640976 endingPage "4226" @default.
• W792640976 startingPage "4226" @default.
• W792640976 abstract "Abstract Many tumor cells are dependent on glutamine (Gln) for growth and survival. Gln is the most abundant amino acid in plasma and tumor cells can utilize Gln for energy production and generation of building blocks for the synthesis of macromolecules. A key step in Gln utilization is its conversion to glutamate (Glu) by the mitochondrial enzyme glutaminase (GLS). Suppressing GLS activity via either siRNA knockdown or small molecule inhibitor treatment has anti-proliferative activity in several tumor types. GLS mRNA levels are elevated in several hematological malignances, particularly those derived from the B-cell lineage including multiple myeloma (MM), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and several types of non-Hodgkin’s lymphoma (NHL). Interestingly, these B-cell derived tumors express low levels of glutamine synthetase (GLUL), an enzyme that reverses the action of GLS by converting Glu to Gln. A high GLS/low GLUL mRNA expression pattern may be indicative of tumor-dependence on extracellular Gln for growth. This expression pattern is observed in triple negative breast cancer (TNBC), a tumor type that we and others have shown to be highly dependent on exogenous Gln for cell proliferation and sensitive to GLS inhibitor treatment. CB-839 is a novel, potent, orally bioavailable GLS inhibitor that inhibits recombinant human GLS with an IC50 of 15 nM. The anti-proliferative activity of CB-839 on a panel of breast cell lines is correlated with a high ratio of GLS to GLUL expression, a pattern associated with the TNBC subtype. Given the similarity of the GLS/GLUL expression pattern observed in TNBC with some hematologic malignancies, we evaluated the anti-tumor activity of CB-839 in cell culture and xenograft models of hematological malignancies predicted to be dependent on Gln for growth. Across a panel of 18 cell lines derived from MM, ALL and diffuse large B-cell lymphoma (DLBCL), Gln deprivation resulted in a minimum of 70% reduction in growth for 16 cell lines and induced cell death in 5 cell lines. Across the same panel of cell lines, the majority were sensitive to CB-839 treatment with 16 cell lines exhibiting an antiproliferative IC50 of<100nM (range 2-72 nM). Importantly, there was a strong correlation between sensitivity to Gln withdrawal and CB-839 sensitivity (r=0.63, p=0.005), suggesting that the dominant pathway by which Gln supports tumor cell growth and survival is through its conversation to Glu by GLS. Consistent with this notion, CB-839 treatment caused a decrease in the intracellular pool of Glu and an increase in the intracellular pool of Gln. The extent of decrease in Glu was highly correlated with the effect of CB-839 on cell proliferation (r=-0.64, p=0.006). The in vivo antitumor activity of CB-839 was also evaluated in a xenograft model using the multiple myeloma RPMI-8226 model. Oral, twice daily dosing of CB-839 resulted in a significant decrease in tumor volume (70% tumor growth inhibition). As observed in vitro, CB-839 dosing caused an increase in tumor Gln levels and a decrease in the level of tumor Glu. In a dose dependent fashion, there was a correlation between tumor Gln accumulation, tumor GLS inhibition and antitumor activity. Efficacious doses of CB-839 were well tolerated with no effect on hematological cell counts or body weight. These data suggest that GLS inhibition with CB-839 may provide therapeutic benefit in hematological malignances and motivate the evaluation of this compound in clinical trials that include patients with B-cell malignancies. Disclosures: Parlati: Calithera BIosciences: Employment. Bromley-Dulfano:Calithera Biosciences: Employment. Demo:Calithera Biosciences: Employment. Janes:Calithera Biosciences: Employment. Gross:Calithera Biosciences: Employment. Lewis:Calithera Biosciences: Employment. MacKinnon:Calithera Biosciences: Employment. Rodriguez:Calithera Biosciences: Employment. Yang:Calithera Biosciences: Employment. Zhao:Calithera Biosciences: Employment. Bennett:Calithera Biosciences: Employment." @default.
• W792640976 created "2016-06-24" @default.
• W792640976 creator A5005410943 @default.
• W792640976 creator A5013456495 @default.
• W792640976 creator A5013905850 @default.
• W792640976 creator A5028427893 @default.
• W792640976 creator A5043061822 @default.
• W792640976 creator A5051839719 @default.
• W792640976 creator A5055304416 @default.
• W792640976 creator A5078566374 @default.
• W792640976 creator A5079083850 @default.
• W792640976 creator A5081005386 @default.
• W792640976 creator A5083336879 @default.
• W792640976 date "2013-11-15" @default.
• W792640976 modified "2023-10-12" @default.
• W792640976 title "Antitumor Activity Of The Glutaminase Inhibitor CB-839 In Hematological Malignances" @default.
• W792640976 doi "https://doi.org/10.1182/blood.v122.21.4226.4226" @default.
• W792640976 hasPublicationYear "2013" @default.
• W792640976 type Work @default.
• W792640976 sameAs 792640976 @default.
• W792640976 citedByCount "17" @default.
• W792640976 countsByYear W7926409762017 @default.
• W792640976 countsByYear W7926409762019 @default.
• W792640976 countsByYear W7926409762020 @default.
• W792640976 countsByYear W7926409762021 @default.
• W792640976 countsByYear W7926409762022 @default.
• W792640976 countsByYear W7926409762023 @default.
• W792640976 crossrefType "journal-article" @default.
• W792640976 hasAuthorship W792640976A5005410943 @default.
• W792640976 hasAuthorship W792640976A5013456495 @default.
• W792640976 hasAuthorship W792640976A5013905850 @default.
• W792640976 hasAuthorship W792640976A5028427893 @default.
• W792640976 hasAuthorship W792640976A5043061822 @default.
• W792640976 hasAuthorship W792640976A5051839719 @default.
• W792640976 hasAuthorship W792640976A5055304416 @default.
• W792640976 hasAuthorship W792640976A5078566374 @default.
• W792640976 hasAuthorship W792640976A5079083850 @default.
• W792640976 hasAuthorship W792640976A5081005386 @default.
• W792640976 hasAuthorship W792640976A5083336879 @default.
• W792640976 hasConcept C109549099 @default.
• W792640976 hasConcept C185592680 @default.
• W792640976 hasConcept C203014093 @default.
• W792640976 hasConcept C2776364478 @default.
• W792640976 hasConcept C2777938653 @default.
• W792640976 hasConcept C2778160063 @default.
• W792640976 hasConcept C2778461978 @default.
• W792640976 hasConcept C2779349466 @default.
• W792640976 hasConcept C502942594 @default.
• W792640976 hasConcept C515207424 @default.
• W792640976 hasConcept C54355233 @default.
• W792640976 hasConcept C55493867 @default.
• W792640976 hasConcept C62112901 @default.
• W792640976 hasConcept C81885089 @default.
• W792640976 hasConcept C86803240 @default.
• W792640976 hasConceptScore W792640976C109549099 @default.
• W792640976 hasConceptScore W792640976C185592680 @default.
• W792640976 hasConceptScore W792640976C203014093 @default.
• W792640976 hasConceptScore W792640976C2776364478 @default.
• W792640976 hasConceptScore W792640976C2777938653 @default.
• W792640976 hasConceptScore W792640976C2778160063 @default.
• W792640976 hasConceptScore W792640976C2778461978 @default.
• W792640976 hasConceptScore W792640976C2779349466 @default.
• W792640976 hasConceptScore W792640976C502942594 @default.
• W792640976 hasConceptScore W792640976C515207424 @default.
• W792640976 hasConceptScore W792640976C54355233 @default.
• W792640976 hasConceptScore W792640976C55493867 @default.
• W792640976 hasConceptScore W792640976C62112901 @default.
• W792640976 hasConceptScore W792640976C81885089 @default.
• W792640976 hasConceptScore W792640976C86803240 @default.
• W792640976 hasIssue "21" @default.
• W792640976 hasLocation W7926409761 @default.
• W792640976 hasOpenAccess W792640976 @default.
• W792640976 hasPrimaryLocation W7926409761 @default.
• W792640976 hasRelatedWork W1587484222 @default.
• W792640976 hasRelatedWork W2040076847 @default.
• W792640976 hasRelatedWork W2135115897 @default.
• W792640976 hasRelatedWork W2563696845 @default.
• W792640976 hasRelatedWork W2589122682 @default.
• W792640976 hasRelatedWork W2810917879 @default.
• W792640976 hasRelatedWork W2914007480 @default.
• W792640976 hasRelatedWork W3095609398 @default.
• W792640976 hasRelatedWork W3202862753 @default.
• W792640976 hasRelatedWork W4231382750 @default.
• W792640976 hasVolume "122" @default.
• W792640976 isParatext "false" @default.
• W792640976 isRetracted "false" @default.
• W792640976 magId "792640976" @default.
• W792640976 workType "article" @default.